Pharmacokinetics, activity, and safety of ODM-201 in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: An open-label phase I trial with long-term extension.

被引：0
|
作者：
Massard, Christophe
Penttinen, Heidi
Bono, Petri
Vjaters, Egils
Lietuvietis, Vilnis
Tammela, Teuvo L. J.
Vuorela, Annamari
Nykanen, Pirjo
Pohjanjousi, Pasi
Fizazi, Karim
机构：
[1] Univ Paris 11, Inst Gustave Roussy, Villejuif, France
[2] Univ Helsinki, Cent Hosp, Ctr Canc, Helsinki, Finland
[3] P Stradins Clin Univ Hosp, Riga, Latvia
[4] Riga East Univ Hosp, Riga, Latvia
[5] Tampere Univ Hosp, Tampere, Finland
[6] Orion Corp Orion Pharma, Espoo, Finland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.230
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
230
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
    Beer, Tomasz M.
    Armstrong, Andrew J.
    Rathkopf, Dana
    Loriot, Yohann
    Sternberg, Cora N.
    Higano, Celestia S.
    Iversen, Peter
    Evans, Christopher P.
    Kim, Choung-Soo
    Kimura, Go
    Miller, Kurt
    Saad, Fred
    Bjartell, Anders S.
    Borre, Michael
    Mulders, Peter
    Tammela, Teuvo L.
    Parli, Teresa
    Sari, Suha
    van Os, Steve
    Theeuwes, Ad
    Tombal, Bertrand
    EUROPEAN UROLOGY, 2017, 71 (02) : 151 - 154
  • [42] A phase I open-label study using lenalidomide and docetaxel in castration-resistant prostate cancer
    Petrylak, D. P.
    Resto-Garces, K.
    Tibyan, M.
    Mohile, S. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [43] A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer
    Pook, David
    Geynisman, Daniel M.
    Carles, Joan
    de Braud, Filippo
    Joshua, Anthony M.
    Perez-Gracia, Jose Luis
    Perez, Casilda Llacer
    Shin, Sang Joon
    Fang, Bruno
    Barve, Minal
    Maruzzo, Marco
    Bracarda, Sergio
    Kim, Miso
    Kerloeguen, Yannick
    Gallo, Jorge Daniel
    Maund, Sophia L.
    Harris, Adam
    Huang, Kuan-Chieh
    Poon, Victor
    Sutaria, Dhruvitkumar S.
    Gurney, Howard
    CLINICAL CANCER RESEARCH, 2023, 29 (17) : 3292 - 3300
  • [44] The PREVAIL trial of enzalutamide (ENZA) in men with chemotherapy-naive, metastatic castration-resistant prostate cancer (mCRPC): subgroup analysis of Asian patients
    Kim, Choung-soo
    Choi, Young Deuk
    Lee, Sangchul
    Lee, Hyun Moo
    Ueda, Takeshi
    Yonese, Junji
    Fukagai, Takashi
    Mansbach, Harry
    Theeuwes, Ad
    Beer, Tomasz M.
    Tombal, Bertrand
    Kimura, Go
    BJU INTERNATIONAL, 2015, 116 : 14 - 14
  • [45] Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study
    Cindolo, Luca
    Natoli, Clara
    De Nunzio, Cosimo
    De Tursi, Michele
    Valeriani, Maurizio
    Giacinti, Silvana
    Micali, Salvatore
    Rizzo, Mino
    Bianchi, Giampaolo
    Martorana, Eugenio
    Scarcia, Marcello
    Ludovico, Giuseppe Mario
    Bove, Pierluigi
    Laudisi, Anastasia
    Selvaggio, Oscar
    Carrieri, Giuseppe
    Bada, Maida
    Castellan, Pietro
    Boccasile, Stefano
    Ditonno, Pasquale
    Chiodini, Paolo
    Verze, Paolo
    Mirone, Vincenzo
    Schips, Luigi
    BMC CANCER, 2017, 17
  • [46] Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter “real life” study
    Luca Cindolo
    Clara Natoli
    Cosimo De Nunzio
    Michele De Tursi
    Maurizio Valeriani
    Silvana Giacinti
    Salvatore Micali
    Mino Rizzo
    Giampaolo Bianchi
    Eugenio Martorana
    Marcello Scarcia
    Giuseppe Mario Ludovico
    Pierluigi Bove
    Anastasia Laudisi
    Oscar Selvaggio
    Giuseppe Carrieri
    Maida Bada
    Pietro Castellan
    Stefano Boccasile
    Pasquale Ditonno
    Paolo Chiodini
    Paolo Verze
    Vincenzo Mirone
    Luigi Schips
    BMC Cancer, 17
  • [47] Subgroup analyses of Japanese patients from the PREVAIL trial of enzalutamide (ENZA) in patients with chemotherapy-naive, metastatic castration-resistant prostate cancer (mCRPC).
    Kimura, Go
    Yonese, Junji
    Fukagai, Takashi
    Kamba, Tomomi
    Nishimura, Kazuo
    Nozawa, Masahiro
    Mansbach, Harry H.
    Phung, De
    Beer, Tomasz M.
    Tombal, Bertrand F.
    Ueda, Takeshi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [48] Phase-1 study of abiraterone acetate in chemotherapy-naive Japanese patients with castration-resistant prostate cancer
    Matsubara, Nobuaki
    Uemura, Hiroji
    Fukui, Iwao
    Niwakawa, Masashi
    Yamaguchi, Akito
    Iizuka, Koho
    Akaza, Hideyuki
    CANCER SCIENCE, 2014, 105 (10) : 1313 - 1320
  • [49] Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
    Petrylak, Daniel P.
    Loriot, Yohann
    Shaffer, David R.
    Braiteh, Fadi
    Powderly, John
    Harshman, Lauren C.
    Conkling, Paul
    Delord, Jean-Pierre
    Gordon, Michael
    Kim, Joseph W.
    Sarkar, Indrani
    Yuen, Kobe
    Kadel, Edward E.
    Mariathasan, Sanjeev
    O'Hear, Carol
    Narayanan, Sujata
    Fasso, Marcella
    Carroll, Susheela
    Powles, Thomas
    CLINICAL CANCER RESEARCH, 2021, 27 (12) : 3360 - 3369
  • [50] Lenalidomide Monotherapy in Chemotherapy-Naive, Castration-Resistant Prostate Cancer Patients: Final Results of a Phase II Study
    Nabhan, Chadi
    Patel, Anand
    Villines, Dana
    Tolzien, Kathy
    Kelby, Susan K.
    Lestingi, Timothy M.
    CLINICAL GENITOURINARY CANCER, 2014, 12 (01) : 27 - 32
12345